Lance Inc.

ASSEMBLY, A STAGWELL (STGW) AGENCY, WELCOMES THREE NEW MANAGING PARTNERS IN EUROPE

Retrieved on: 
Monday, September 11, 2023
Advertising, Appleby, Amazon Web Services, Hopkins, Huawei, Sainsbury, Assembly, Partner, Dentsu, BlackRock, Partner (business rank), Rufus, McVitie, Carbon, PHD, Government, UK Government Decontamination Service, Xerox, DE, Amazon, WaveMaker, Retail, Government of the United Kingdom, Sustainability, Vodafone, ESG, Digital, Growth, Mitchell, Amazon Prime Video, Mental health, Management, Lance Inc., Peroni

LONDON, Sept. 11, 2023 /PRNewswire/ -- Assembly announced today the addition of James Appleby, Alex Boniface, and Bridget Hopkins – three new Managing Partners in Europe who will play pivotal roles in shaping the agency's future, fostering innovation, enhancing operations, and driving sustainable growth. Each leader comes with extensive experience across specialisms, and their combined vision and leadership will allow Assembly to continue delivering brand performance for clients and further expand the agency's presence in the European region. Appleby, Boniface, and Hopkins are based in London and will report to Matt Adams, Assembly Europe CEO.

Key Points: 
  • Appleby, Boniface, and Hopkins are based in London and will report to Matt Adams, Assembly Europe CEO.
  • In his last role, he was Head of Client Success at Tailify, an influencer marketing company.
  • Before joining Assembly, Hopkins established her media career in Australia, working at Mitchell & Partners, an agency later acquired by Dentsu.
  • Assembly Europe CEO Matt Adams adds, "We are thrilled to welcome James, Alex, and Bridget into the Assembly family.

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Wednesday, May 4, 2022
Degenerative disease, Synthetic biological circuit, AMR, Private Securities Litigation Reform Act, Maintenance, GLOBE, ICO, Company, NYSE, Neoplasm, Cell, Safety, Time, Clostridioides difficile infection, CGMP, NAB, Gene, IAP, Clinical trial, Program, Immunotherapy, Annual report, Therapy, CDI, HCT, VCN, Marketing, Society, Sale, IV, SYN, SEC, Terminology, Toxicity, Growth, Lance, Acquisition, Pharmaceutical industry, Vaccine, Lance Inc.

ROCKVILLE, Md., May 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced an upcoming oral presentation on novel oncolytic adenovirus VCN-11 at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.

Key Points: 
  • We are excited to present new data on VCN-11, which should further position us at the forefront of oncolytic virus development, said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics.
  • VCN-11 is a next-generation adenovirus that is genetically modified to express hyaluronidase and degrade the protective tumor stroma barrier.
  • We look forward to building upon our foundation of compelling proof-of-mechanism data and continuing to advance our oncolytic adenovirus (OV) program through clinical development.
  • The full abstract (# 98 ) is accessible on the ASGCT conference portal and details for the oral presentation are included below.

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

Retrieved on: 
Thursday, October 21, 2021
Safety, Phenylalanine, RNA transfection, Method, TI, LAMP1, Lance Inc., Prevalence, GLP, MPS, Hunter syndrome, Disease, PKU, Failure, PAH, Dose, Hematopoietic stem cell transplantation, Paroxysmal nocturnal hemoglobinuria, CNS, Glycogen storage disease, Phenix, Patient, ESGCT, Private Securities Litigation Reform Act, II, Clinical trial, Antibody, SEC, MPS II, Microdeletion syndrome, Cell, Purkinje, PNH, Lance, Conference, Brain, Immunoglobulin G, Company, I2S, Cell Loss Priority, COVID-19, Gene, ASHG, Nasdaq, Therapy, Population, GLOBE, Cerebellum, European Society of Gene and Cell Therapy, Liver, Gene editing, Hepatocyte, Vaccine, Pharmaceutical industry, Medical imaging, Dietary supplement

BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), clinical-stage gene editing program for phenylketonuria (PKU), GTx-mAb program for paroxysmal nocturnal hemoglobinuria (PNH) and assays to evaluate levels of pre-existing antibodies to the Company’s adeno-associated viral vectors (AAVHSCs) during the 2021 European Society for Gene & Cell Therapy Virtual Conference (ESGCT).

Key Points: 
  • gene therapy candidate for MPS II, and showcased gene editing data in the PKU and humanized murine models, including on- and off-target assessment confirming the precision of our nuclease-free in vivo gene editing.
  • Encouraging data from our GTx-mAb platform showed a single dose resulted in sustained and robust expression of full-length antibodies from the liver consistent with anti-C5 therapeutics.
  • Further, we presented details of the methods of our neutralizing antibody assays used in our clinical trial screening.
  • Both methods are used in the screening phase of Homologys HMI-102 gene therapy pheNIX clinical trial to determine patient eligibility based on pre-existing Nabs.